{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:48:32Z","timestamp":1791942512377,"version":"4.3.4"},"reference-count":38,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273084"],"award-info":[{"award-number":["82273084"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404358"],"award-info":[{"award-number":["82404358"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n \n Keverprazan, a novel potassium\u2010competitive acid blocker (P\u2010CAB), provides stronger and more sustained gastric acid suppression than proton pump inhibitors (PPIs). However, direct comparisons between 14\u2010day keverprazan\u2010amoxicillin (KA) dual therapy and 14\u2010day bismuth\u2010containing quadruple therapy (BQT) for\n \n Helicobacter pylori<\/jats:italic>\n <\/jats:styled-content>\n (\n \n H. pylori<\/jats:italic>\n <\/jats:styled-content>\n ) eradication remain limited.\n <\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n \n This study compared the efficacy and safety of the 14\u2010day KA dual therapy versus BQT as a first\u2010line therapy for\n \n H. pylori<\/jats:italic>\n <\/jats:styled-content>\n eradication.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This randomized controlled trial (RCT) recruited 316 treatment\u2010naive,\n \n H. pylori<\/jats:italic>\n <\/jats:styled-content>\n \u2010infected patients. Participants were randomly assigned to receive either the KA group (keverprazan 20\u2009mg twice daily\u2009+\u2009amoxicillin 1000\u2009mg three times daily) or the BQT group (esomeprazole 20\u2009mg twice daily\u2009+\u2009amoxicillin 1000\u2009mg twice daily\u2009+\u2009clarithromycin 500\u2009mg twice daily\u2009+\u2009colloidal bismuth pectin 300\u2009mg twice daily).\n \n H. pylori<\/jats:italic>\n <\/jats:styled-content>\n eradication rate was the primary outcome. Adverse events and compliance were considered as secondary outcomes.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n KA dual therapy was noninferior to BQT in eradication rates across intention\u2010to\u2010treat (ITT) analysis (85.4% vs. 82.9%, noninferiority\n p<\/jats:italic>\n \u2009=\u20090.001), modified intention\u2010to\u2010treat (MITT) analysis (92.5% vs. 92.9%, noninferiority\n p<\/jats:italic>\n \u2009<\u20090.001), and per\u2010protocol (PP) analysis (93.7% vs. 93.5%, noninferiority\n p<\/jats:italic>\n \u2009<\u20090.001). Adverse events were significantly lower in the KA group (19.0%) than in the BQT group (28.5%),\n p<\/jats:italic>\n \u2009=\u20090.047.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n The trial suggested KA dual therapy was a promising first\u2010line therapy, achieving a 93.7% eradication rate in the PP analysis, with favorable safety and similar compliance compared to BQT.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n Chinese Clinical Trial Registry: ChiCTR2400089303<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/jgh.70808","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:41:27Z","timestamp":1791942087000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["14\u2010Day Keverprazan\u2013Amoxicillin Dual Therapy Versus Bismuth\u2010Containing Quadruple Therapy as First\u2010Line Treatment for\n \n Helicobacter pylori<\/i>\n <\/scp>\n Eradication: A Prospective, Single\u2010Center, Randomized Controlled Trial"],"prefix":"10.1111","author":[{"given":"Yue","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Gastroenterology The Affiliated Hospital of Yangzhou University, Yangzhou University Yangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"She","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology The Affiliated Hospital of Yangzhou University, Yangzhou University Yangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0689-2199","authenticated-orcid":false,"given":"Yan\u2010Bing","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology The Affiliated Hospital of Yangzhou University, Yangzhou University Yangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology The Affiliated Hospital of Yangzhou University, Yangzhou University Yangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao\u2010Yao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology The Affiliated Hospital of Yangzhou University, Yangzhou University Yangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo\u2010Qi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology The Affiliated Hospital of Yangzhou University, Yangzhou University Yangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing\u2010Wen","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology The Affiliated Hospital of Yangzhou University, Yangzhou University Yangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[{"name":"Maji Health Center Yangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen\u2010Bin","family":"Yang","sequence":"additional","affiliation":[{"name":"Yangzhou Hospital of Traditional Chinese Medicine Yangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun\u2010Hua","family":"Liu","sequence":"additional","affiliation":[{"name":"Baoying County People's Hospital Yangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6096-3034","authenticated-orcid":false,"given":"Ben\u2010Gang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Northern Jiangsu People's Hospital Yangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4161-2746","authenticated-orcid":false,"given":"Xin","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology The Affiliated Hospital of Yangzhou University, Yangzhou University Yangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"e_1_2_13_2_1","unstructured":"N. S.ParikhandR.Ahlawat \u201cHelicobacter pylori \u201d StatPearls. Treasure Island (FL): StatPearls Publishing Copyright 2025 StatPearls Publishing LLC. (2025)."},{"key":"e_1_2_13_3_1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S2468-1253(23)00070-5","article-title":"Global Prevalence of Helicobacter pylori Infection Between 1980 and 2022: A Systematic Review and meta\u2010Analysis","volume":"8","author":"Li Y.","year":"2023","journal-title":"Lancet Gastroenterology & Hepatology"},{"key":"e_1_2_13_4_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032895","article-title":"Helicobacter pylori and Gastric Cancer: Pathogenetic Mechanisms","volume":"24","author":"Salvatori S.","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"key":"e_1_2_13_5_1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4166\/kjg.2023.097","article-title":"Helicobacter pylori\u2010Associated Chronic Atrophic Gastritis and Progression of Gastric Carcinogenesis","volume":"82","author":"Lim N. R.","year":"2023","journal-title":"Korean Journal of Gastroenterology"},{"key":"e_1_2_13_6_1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1053\/j.gastro.2023.12.022","article-title":"Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022","volume":"166","author":"Chen Y. C.","year":"2024","journal-title":"Gastroenterology"},{"key":"e_1_2_13_7_1","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.3748\/wjg.v30.i43.4636","article-title":"Prevalence of Helicobacter pylori Infection in China From 2014\u20102023: A Systematic Review and Meta\u2010Analysis","volume":"30","author":"Xie L.","year":"2024","journal-title":"World Journal of Gastroenterology"},{"key":"e_1_2_13_8_1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2016.563","article-title":"ACG Clinical Guideline: Treatment of Helicobacter pylori Infection","volume":"112","author":"Chey W. D.","year":"2017","journal-title":"American Journal of Gastroenterology"},{"key":"e_1_2_13_9_1","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1097\/CM9.0000000000002546","article-title":"2022 Chinese National Clinical Practice Guideline on Helicobacter pylori Eradication Treatment","volume":"135","author":"Zhou L.","year":"2022","journal-title":"Chinese Medical Journal"},{"key":"e_1_2_13_10_1","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori Infection: The Maastricht VI\/Florence Consensus Report","volume":"71","author":"Malfertheiner P.","year":"2022","journal-title":"Gut"},{"key":"e_1_2_13_11_1","first-page":"9","article-title":"Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance","volume":"9","author":"Kim S. Y.","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"e_1_2_13_12_1","first-page":"5027","article-title":"A Retrospective Study of the Antibiotic\u2010Resistant Phenotypes and Genotypes of Helicobacter pylori Strains in China","volume":"11","author":"Zhong Z.","year":"2021","journal-title":"American Journal of Cancer Research"},{"key":"e_1_2_13_13_1","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12714","article-title":"The Effect of Antibiotic Resistance on Helicobacter pylori Eradication Efficacy: A Systematic Review and Meta\u2010Analysis","volume":"25","author":"Zou Y.","year":"2020","journal-title":"Helicobacter"},{"key":"e_1_2_13_14_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119433","article-title":"Helicobacter pylori Antibiotic Resistance: Molecular Basis and Diagnostic Methods","volume":"24","author":"Medakina I.","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"key":"e_1_2_13_15_1","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jmii.2024.02.009","article-title":"The Multicenter Real\u2010World Report of the Efficacies of 14\u2010Day Esomeprazole\u2010Based and Rabeprazole\u2010Based High\u2010Dose Dual Therapy in First\u2010Line Helicobacter pylori Eradication in Taiwan","volume":"57","author":"Tai W. C.","year":"2024","journal-title":"Journal of Microbiology, Immunology, and Infection"},{"key":"e_1_2_13_16_1","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s40121-023-00811-3","article-title":"The Efficacy and Safety of 14\u2010Day Rabeprazole Plus Amoxicillin High Dose Dual Therapy by Comparing to 14\u2010Day Rabeprazole\u2010Containing Hybrid Therapy for the Na\u00efve Helicobacter pylori Infection in Taiwan: A Randomized Controlled Trial","volume":"12","author":"Tai W. C.","year":"2023","journal-title":"Infectious Disease and Therapy"},{"key":"e_1_2_13_17_1","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/MCG.0000000000002100","article-title":"Clinical Impact of High\u2010Dose Esomeprazole\u2010Amoxicillin Dual Therapy as Rescue Treatment for Helicobacter pylori Infection: A Prospective, Multicenter, Randomized Trial","volume":"59","author":"Wang C.","year":"2025","journal-title":"Journal of Clinical Gastroenterology"},{"key":"e_1_2_13_18_1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11894-024-00939-3","article-title":"Potassium\u2010Competitive Acid Blockers: Current Clinical Use and Future Developments","volume":"26","author":"Scarpignato C.","year":"2024","journal-title":"Current Gastroenterology Reports"},{"key":"e_1_2_13_19_1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.4103\/sjg.sjg_297_23","article-title":"Unlocking the Path to Efficient H. pylori Eradication: Embracing Potassium\u2010Competitive Acid Blockers (P\u2010CABs)","volume":"29","author":"Borody T. J.","year":"2023","journal-title":"Saudi Journal of Gastroenterology"},{"key":"e_1_2_13_20_1","doi-asserted-by":"crossref","DOI":"10.1177\/17562848241241223","article-title":"P\u2010CAB Versus PPI in the Eradication of Helicobacter pylori: A Systematic Review and Network Meta\u2010Analysis","volume":"17","author":"Jiang Y.","year":"2024","journal-title":"Therapeutic Advances in Gastroenterology"},{"key":"e_1_2_13_21_1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5056\/jnm18139","article-title":"Role of Acid Suppression in Acid\u2010Related Diseases: Proton Pump Inhibitor and Potassium\u2010Competitive Acid Blocker","volume":"25","author":"Mori H.","year":"2019","journal-title":"Journal of Neurogastroenterology and Motility"},{"key":"e_1_2_13_22_1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40262-015-0326-7","article-title":"The First\u2010in\u2010Class Potassium\u2010Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations","volume":"55","author":"Echizen H.","year":"2016","journal-title":"Clinical Pharmacokinetics"},{"key":"e_1_2_13_23_1","doi-asserted-by":"crossref","DOI":"10.1111\/hel.13040","article-title":"Vonoprazan\u2010Amoxicillin Dual Therapy Versus Bismuth\u2010Containing Quadruple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta\u2010Analysis","volume":"29","author":"Zhou B. G.","year":"2024","journal-title":"Helicobacter"},{"key":"e_1_2_13_24_1","doi-asserted-by":"crossref","DOI":"10.1111\/hel.70100","article-title":"Efficacy and Safety of Keverprazan\u2010Amoxicillin Dual Regimen in Initial Eradication of Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial","volume":"31","author":"Wei S.","year":"2026","journal-title":"Helicobacter"},{"key":"e_1_2_13_25_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107320","article-title":"The Efficacy of Keverprazan\u2010Based Quadruple Therapy for Helicobacter pylori Eradication: A Phase III, Randomised, Double\u2010Blind, Multicentre Trial","volume":"64","author":"Tan N.","year":"2024","journal-title":"International Journal of Antimicrobial Agents"},{"key":"e_1_2_13_26_1","doi-asserted-by":"crossref","DOI":"10.1177\/17562848241309870","article-title":"Ten\u2010Day Vonoprazan\u2010Amoxicillin Dual Therapy Versus 14\u2010Day Esomeprazole\u2010Amoxicillin Dual Therapy for First\u2010Line Helicobacter pylori Eradication: A Prospective Multicenter Randomized Controlled Trial","volume":"17","author":"Zhou B. G.","year":"2024","journal-title":"Therapeutic Advances in Gastroenterology"},{"key":"e_1_2_13_27_1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.14309\/ajg.0000000000002086","article-title":"Ten\u2010Day Vonoprazan\u2010Amoxicillin Dual Therapy as a First\u2010Line Treatment of Helicobacter pylori Infection Compared With Bismuth\u2010Containing Quadruple Therapy","volume":"118","author":"Qian H. S.","year":"2023","journal-title":"American Journal of Gastroenterology"},{"key":"e_1_2_13_28_1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.14309\/ajg.0000000000002298","article-title":"It Is Time for a Paradigm Shift in Design, Execution, and Publishing of Comparative Helicobacter pylori Treatment Trials","volume":"118","author":"Graham D. Y.","year":"2023","journal-title":"American Journal of Gastroenterology"},{"key":"e_1_2_13_29_1","doi-asserted-by":"crossref","DOI":"10.1111\/hel.13039","article-title":"Vonoprazan and Amoxicillin Dual Therapy as the First\u2010Line Treatment of Helicobacter pylori Infection: A Systematic Review and Meta\u2010Analysis","volume":"29","author":"Du R. C.","year":"2024","journal-title":"Helicobacter"},{"key":"e_1_2_13_30_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2023.102125","article-title":"Comparing High\u2010Dose Dual Therapy With Bismuth\u2010Containing Quadruple Therapy for the Initial Eradication of Helicobacter pylori Infection on Hainan Island: A Randomized, Multicenter Clinical Trial","volume":"47","author":"Liu D. N.","year":"2023","journal-title":"Clinics and Research in Hepatology and Gastroenterology"},{"key":"e_1_2_13_31_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062162","article-title":"Effects of CYP2C19 Loss\u2010of\u2010Function Variants on the Eradication of H. pylori Infection in Patients Treated With Proton Pump Inhibitor\u2010Based Triple Therapy Regimens: A meta\u2010Analysis of Randomized Clinical Trials","volume":"8","author":"Tang H. L.","year":"2013","journal-title":"PLoS ONE"},{"key":"e_1_2_13_32_1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.759249","article-title":"Influence of Cytochrome P450 2C19 Genotype on Helicobacter pylori Proton Pump Inhibitor\u2010Amoxicillin\u2010Clarithromycin Eradication Therapy: A Meta\u2010Analysis","volume":"12","author":"Morino Y.","year":"2021","journal-title":"Frontiers in Pharmacology"},{"key":"e_1_2_13_33_1","doi-asserted-by":"crossref","DOI":"10.1111\/hel.13151","article-title":"Tegoprazan\u2010Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Prospective, Randomized, Multicenter Study in Fujian, China","volume":"29","author":"Lin X.","year":"2024","journal-title":"Helicobacter"},{"key":"e_1_2_13_34_1","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00535-023-02042-2","article-title":"Comparison of Vonoprazan\u2010Based With Rabeprazole\u2010Based Dual Therapy for Treatment\u2010Naive Patients of Helicobacter pylori Infection: A Prospective, Multi\u2010Center, Randomized Controlled Study","volume":"58","author":"Han Y. Y.","year":"2023","journal-title":"Journal of Gastroenterology"},{"key":"e_1_2_13_35_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/ph17060698","article-title":"Comparative Efficacy and Safety of Potassium\u2010Competitive Acid Blockers vs. Proton Pump Inhibitors for Peptic Ulcer With or Without Helicobacter pylori Infection: A Systematic Review and Network Meta\u2010Analysis","volume":"17","author":"Ouyang M.","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"e_1_2_13_36_1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1580969","article-title":"Clinical Pharmacokinetics of Potassium Competitive Acid Blockers: A Systematic Review and Meta\u2010Analysis","volume":"16","author":"Liu J.","year":"2025","journal-title":"Frontiers in Pharmacology"},{"key":"e_1_2_13_37_1","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.14309\/ajg.0000000000002968","article-title":"ACG Clinical Guideline: Treatment of Helicobacter pylori Infection","volume":"119","author":"Chey W. D.","year":"2024","journal-title":"American Journal of Gastroenterology"},{"key":"e_1_2_13_38_1","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231190976","article-title":"Efficacy and Safety of Vonoprazan\u2010Amoxicillin Dual Therapy for Helicobacter pylori First\u2010Line Treatment: A Single\u2010Center, Randomized, Controlled Trial","volume":"16","author":"Wang X.","year":"2023","journal-title":"Therapeutic Advances in Gastroenterology"},{"key":"e_1_2_13_39_1","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/apt.13588","article-title":"Potent Acid Inhibition by Vonoprazan in Comparison With Esomeprazole, With Reference to CYP2C19 Genotype","volume":"43","author":"Kagami T.","year":"2016","journal-title":"Alimentary Pharmacology & Therapeutics"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgh.70808","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jgh.70808","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgh.70808","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:41:32Z","timestamp":1791942092000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jgh.70808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":38,"alternative-id":["10.1111\/jgh.70808"],"URL":"https:\/\/doi.org\/10.1111\/jgh.70808","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"2026-03-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"jgh.70808"}}